CIK 0001439222 · Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-02-27 | Biller Scott Chief Scientific Officer | Sale | −9,000 | $65.00 | $585K | 26,511 |
| 2019-02-27 | Biller Scott Chief Scientific Officer | Option exercise · Stock option (right to buy) | −1,766 | 0 | ||
| 2019-02-27 | Biller Scott Chief Scientific Officer | Option exercise · Stock option (right to buy) | −4,154 | 0 | ||
| 2019-02-27 | Biller Scott Chief Scientific Officer | Option exercise · Stock option (right to buy) | −3,080 | 11,782 | ||
| 2019-02-22 | Hirsch Andrew Chief Financial Officer | Grant or award · Stock option (right to buy) | +40,000 | 40,000 | ||
| 2019-02-22 | Hirsch Andrew Chief Financial Officer | Grant or award · Restricted stock units | +10,000 | 10,000 | ||
| 2019-02-22 | Bowden Christopher Chief Medical Officer | Grant or award · Stock option (right to buy) | +40,000 | 40,000 | ||
| 2019-02-22 | Bowden Christopher Chief Medical Officer | Grant or award · Restricted stock units | +10,000 | 10,000 | ||
| 2019-02-22 | Biller Scott Chief Scientific Officer | Grant or award · Stock option (right to buy) | +40,000 | 40,000 | ||
| 2019-02-22 | Biller Scott Chief Scientific Officer | Grant or award · Restricted stock units | +10,000 | 10,000 | ||
| 2019-02-22 | Alenson Carman Principal Accounting Officer | Grant or award · Stock option (right to buy) | +8,295 | 8,295 | ||
| 2019-02-22 | Alenson Carman Principal Accounting Officer | Grant or award · Restricted stock units | +2,074 | 2,074 | ||
| 2019-02-22 | Schenkein David P Director | Grant or award · Stock option (right to buy) | +45,719 | 45,719 | ||
| 2019-02-22 | Schenkein David P Director | Grant or award · Restricted stock units | +8,324 | 8,324 | ||
| 2019-02-21 | Alenson Carman Principal Accounting Officer | Option exercise | +3,300 | 3,812 | ||
| 2019-02-21 | Alenson Carman Principal Accounting Officer | Shares withheld for taxes | −1,016 | $56.33 | $57K | 2,796 |
| 2019-02-21 | Alenson Carman Principal Accounting Officer | Option exercise · Restricted stock units | −3,300 | 0 | ||
| 2019-02-19 | Schenkein David P Director | Shares withheld for taxes | −2,471 | $58.03 | $143K | 89,503 |
| 2019-02-19 | Hoerter Steven L. Chief Commercial Officer | Shares withheld for taxes | −1,040 | $58.03 | $60K | 10,941 |
| 2019-02-19 | Hirsch Andrew Chief Financial Officer | Shares withheld for taxes | −821 | $58.03 | $48K | 12,374 |
Page 54 of 63 · 1,252 trades